Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
November 23 2009 - 8:30AM
PR Newswire (US)
- LX1031 represents a first-in-class compound for IBS - Inhibitor
of tryptophan hydroxylase, a key enzyme in serotonin production -
First demonstration of new mechanism of action in treatment of IBS
Presentation summary will be available at www.lexpharma.com on
November 25, 2009 THE WOODLANDS, Texas, Nov. 23
/PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
(NASDAQ:LXRX), announced today that top-line data from its Phase 2
clinical study with LX1031 in patients with non-constipating
irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in
London this week. Results from the study, which showed a
significant improvement in IBS symptoms, will be presented by Dr.
Philip M. Brown, Lexicon's senior vice president of clinical
development, on November 25, 2009 at 2:30 pm local time at the
session entitled, "Therapeutic insights in functional digestive
disorders." The GASTRO 2009 meeting is a joint world conference in
the area of gastroenterology. This meeting will bring together the
world's leading organizations - the United European
Gastroenterology Federation (UEGF), World Gastroenterology
Organization (WGO), World Organization of Digestive Endoscopy
(OMED) and the British Society of Gastroenterology (BSG) - for one
of the biggest congresses in this area of medicine with more than
12,000 scientists from around the world expected to attend. A
summary of the GASTRO 2009 presentation (with audio) will be
available on Lexicon's corporate website at
http://www.lexpharma.com/ on November 25, 2009. About LX1031 LX1031
is an orally available, locally acting inhibitor of tryptophan
hydroxylase (TPH), an enzyme necessary for the biosynthesis of
serotonin. LX1031 acts by selectively decreasing the production of
serotonin in the gastrointestinal tract. Discovered and developed
by Lexicon, LX1031 is the first TPH inhibitor ever to be evaluated
in human clinical trials for the treatment of IBS. In Phase 1
clinical trials, all dose levels of the drug were well tolerated,
and no dose-limiting toxicities were observed. LX1031 was also
shown to reduce levels of urinary 5-HIAA, a biomarker of serotonin
production. LX1031 is being developed in collaboration with
Symphony Capital LLC. About Irritable Bowel Syndrome Irritable
bowel syndrome is a disorder most commonly characterized by
cramping, abdominal pain, bloating, constipation or diarrhea.
According to the International Foundation for Functional
Gastrointestinal Disorders, IBS affects between 25 and 45 million
people in the United States. Symptoms of IBS are believed to be
mediated through serotonin, which has been shown to play an
important role in modulating motility and signaling feelings of GI
discomfort. About Lexicon Lexicon is a biopharmaceutical company
focused on discovering and developing breakthrough treatments for
human disease. Lexicon currently has five drug candidates in
development for autoimmune disease, carcinoid syndrome, diabetes,
glaucoma and irritable bowel syndrome, all of which were discovered
by the company's research team. The company has used its
proprietary gene knockout technology to identify more than 100
promising drug targets. Lexicon has focused drug discovery efforts
on these biologically-validated targets to create its extensive
pipeline of clinical and preclinical programs. For additional
information about Lexicon and its programs, please visit
http://www.lexpharma.com/. Safe Harbor Statement This press release
contains "forward-looking statements," including statements
relating to Lexicon's plans for further clinical development of
LX1031 and the potential therapeutic and commercial potential of
LX1031. This press release also contains forward-looking statements
relating to Lexicon's growth and future operating results,
discovery and development of products other than LX1031, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to the clinical
development of LX1031 and preclinical and clinical development of
Lexicon's other potential drug candidates and Lexicon's ability to
successfully advance additional candidates into preclinical and
clinical development, obtain necessary regulatory approvals,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying such
important factors is contained under "Factors Affecting
Forward-Looking Statements" and "Risk Factors" in Lexicon's annual
report on Form 10-K for the year ended December 31, 2008, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.
DATASOURCE: Lexicon Pharmaceuticals, Inc. CONTACT: Jason Ray,
Manager, Corporate Communications and Investor Relations of
Lexicon, +1-281-863-3225, Web Site: http://www.lexpharma.com/
Copyright